The purpose of this study is to compare efficacy of bevacizumab monotherapy with standard
chemotherapy (DTIC) in patients with metastatic malignant melanoma. In addition, we want to
evaluate the predictive value of a set biomarkers associated with vascular endothelial growth
factor (VEGF) dependent angiogenesis. Also, we aim to identify mechanisms causing acquired
resistance to treatment with bevacizumab and escape mechanisms caused by other angiogenic
growth factors than VEGF. Finally, we want to analyze safety and influence on outcome
variables by primary prevention of bevacizumab induced hypertension by low dose beta blockers
in comparison with an ACE inhibitor.
Phase:
Phase 2
Details
Lead Sponsor:
Haukeland University Hospital
Collaborators:
Norwegian Cancer Society The Norwegian Melanoma Group